Logo image of SANA

SANA BIOTECHNOLOGY INC (SANA) Stock Price, Quote, News and Overview

NASDAQ:SANA - Nasdaq - US7995661045 - Common Stock - Currency: USD

3.49  0 (0%)

SANA Quote, Performance and Key Statistics

SANA BIOTECHNOLOGY INC

NASDAQ:SANA (1/24/2025, 2:12:46 PM)

3.49

0 (0%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High12
52 Week Low1.52
Market Cap779.21M
Shares223.27M
Float203.42M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO02-04 2021-02-04


SANA short term performance overview.The bars show the price performance of SANA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 50 100

SANA long term performance overview.The bars show the price performance of SANA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of SANA is 3.49 USD. In the past month the price increased by 111.52%. In the past year, price decreased by -36.2%.

SANA BIOTECHNOLOGY INC / SANA Daily stock chart

SANA Latest News, Press Releases and Analysis

News Image
16 days ago - Chartmill

Top movers in Wednesday's session

Stay up-to-date with the latest market trends one hour before the close of the markets on Wednesday. Explore the top gainers and losers during today's session in our detailed report.

News Image
16 days ago - Chartmill

Let's take a look at the stocks that are in motion in today's session.

What's going on in today's session

News Image
16 days ago - Chartmill

The market is filled with gapping stocks in Wednesday's session. Let's discover which stocks are showing gap-ups and gap-downs.

Let's delve into the US markets on Wednesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

News Image
16 days ago - Chartmill

These stocks are moving in today's pre-market session

Get insights into the top gainers and losers of Wednesday's pre-market session.

News Image
a day ago - Flagship Pioneering

Flagship Pioneering, Cambridge University Health Partners, and Milner Therapeutics Institute Announce Collaboration to Accelerate Biotech Research and Innovation

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced an agreement with top life science organisations Cambridge University...

News Image
4 days ago - MarketBeat

There May Still Be Time to Get in on These 3 Trending Biotechs

Biotech firms as a group declined slightly in the last year amid a tough external environment, but these three companies could grow in 2025.

SANA Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 15.89 301.92B
AMGN AMGEN INC 14.4 148.79B
GILD GILEAD SCIENCES INC 21.11 116.56B
VRTX VERTEX PHARMACEUTICALS INC 860.78 113.06B
REGN REGENERON PHARMACEUTICALS 15.01 74.92B
ARGX ARGENX SE - ADR N/A 39.06B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 35.76B
BNTX BIONTECH SE-ADR N/A 28.89B
ONC BEIGENE LTD-ADR N/A 23.67B
NTRA NATERA INC N/A 22.24B
BIIB BIOGEN INC 8.86 21.08B
SMMT SUMMIT THERAPEUTICS INC N/A 17.71B

About SANA

Company Profile

SANA logo image Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. The company is headquartered in Seattle, Washington and currently employs 328 full-time employees. The company went IPO on 2021-02-04. The company is engaged in developing cell engineering programs to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune and central nervous system disorders. The company develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC291, SC262, SC255, C379, SC451 and UP421. The company is applying its hypoimmune technology to donor derived T cells to be used as allogeneic cell therapies for hematologic malignancies. The company is developing SC255, a B-cell maturation antigen-directed allogeneic CAR T, for the treatment of multiple myeloma. The company is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B-cell malignancies.

Company Info

SANA BIOTECHNOLOGY INC

188 East Blaine Street, Suite 400

Seattle WASHINGTON 98102 US

CEO: Steven D. Harr

Employees: 328

Company Website: https://sana.com/

Investor Relations: https://ir.sana.com/

Phone: 12067017914

SANA FAQ

What is the stock price of SANA?

The current stock price of SANA is 3.49 USD.


What is the symbol for SANA BIOTECHNOLOGY INC stock?

The exchange symbol of SANA BIOTECHNOLOGY INC is SANA and it is listed on the Nasdaq exchange.


On which exchange is SANA stock listed?

SANA stock is listed on the Nasdaq exchange.


Is SANA a good stock to buy?

Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for SANA, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of SANA.


Does SANA stock pay dividends?

SANA does not pay a dividend.


What is the Price/Earnings (PE) ratio of SANA?

SANA does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.36).


What is the Short Interest ratio of SANA stock?

The outstanding short interest for SANA is 18.24% of its float.


SANA Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to SANA. When comparing the yearly performance of all stocks, SANA is a bad performer in the overall market: 87.9% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

SANA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to SANA. While SANA seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SANA Financial Highlights

Over the last trailing twelve months SANA reported a non-GAAP Earnings per Share(EPS) of -1.36. The EPS increased by 1.45% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -54.67%
ROE -104.56%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-1350%
Sales Q2Q%N/A
EPS 1Y (TTM)1.45%
Revenue 1Y (TTM)N/A

SANA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 80% to SANA. The Buy consensus is the average rating of analysts ratings from 13 analysts.


Ownership
Inst Owners90.41%
Ins Owners8.62%
Short Float %18.24%
Short Ratio5.79
Analysts
Analysts80
Price Target10.2 (192.26%)
EPS Next Y12.08%
Revenue Next YearN/A